Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Compugen (CGEN)
:CGEN
CGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $3.03
Previous CloseN/A
Volume276.40K
Average Volume (3M)974.67K
Market Cap
$204.14M
Enterprise Value$52.82M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)116.1
Beta2.22
Next Earnings
Mar 04, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding89,536,430
10 Day Avg. Volume787,650
30 Day Avg. Volume974,670
Standard Deviation0.36
R-Squared0.15
Alpha-0.00905
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.33
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.68
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$4.00Price Target Upside79.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Compugen News
PremiumCompany Announcements
Compugen Ltd. Sets Date for Q4 2024 Financial Results Announcement
PremiumPre-Earnings
Compugen (CGEN) Q4 Earnings Cheat Sheet
PremiumCompany Announcements
Compugen Announces Significant Share Price Increase
PremiumCompany Announcements
Compugen Updates Filing Structure with Bristol Myers Squibb
PremiumCompany Announcements
Compugen Advances COM503 to Phase 1 Clinical Trial in Cancer Treatment
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsAZN's plan to move forward in combinations is encouraging given the early response and durability data in PD-L1 high patients where TIGIT antagonism has demonstrated the greatest activity.
FundingCompugen has received a milestone payment from Gilead, with additional funding expected to support operations into 2027.
Partnership BenefitsCompugen is eligible for up to $200M in development and commercialization milestones spread across the first two rilvegostomig indications.
Bears Say
Management ExpectationsManagement aims to bring down expectations for the upcoming data read-out in platinum-resistant ovarian cancer, despite prior optimistic signals.
Market OversightInvestors are missing the positive data in non-small cell lung cancer (NSCLC) and gastric cancer from Compugen's partner, AZN, presented at ESMO and WCLC.
---
Ownership Overview
―
Insiders
1.57% Mutual Funds
6.57% Other Institutional Investors
89.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGEN FAQ
What was Compugen’s price range in the past 12 months?
Compugen lowest stock price was $1.35 and its highest was $3.03 in the past 12 months.
What is Compugen’s market cap?
Compugen’s market cap is $204.14M.
When is Compugen’s upcoming earnings report date?
Compugen’s upcoming earnings report date is Mar 04, 2025 which is in 12 days.
How were Compugen’s earnings last quarter?
Compugen released its earnings results on Nov 12, 2024. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.095 by $0.105.
Is Compugen overvalued?
According to Wall Street analysts Compugen’s price is currently Undervalued.
Does Compugen pay dividends?
Compugen does not currently pay dividends.
What is Compugen’s EPS estimate?
Compugen’s EPS estimate is -0.08.
How many shares outstanding does Compugen have?
Compugen has 89,536,430 shares outstanding.
What happened to Compugen’s price movement after its last earnings report?
Compugen reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.095. Following the earnings report the stock price went down -8.046%.
Which hedge fund is a major shareholder of Compugen?
Currently, no hedge funds are holding shares in CGEN
---
Compugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (79.37% Upside)
$4.00 (79.37% Upside)
Blogger Sentiment
Bullish
CGEN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.08%
12-Months-Change
Fundamentals
Return on Equity
2.81%
Trailing 12-Months
Asset Growth
82.69%
Trailing 12-Months
Company Description
Compugen
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
---
CGEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant financial improvements and promising clinical data, particularly for COM701 and COM503. However, there remain challenges in treating platinum-resistant ovarian cancer and in refining biomarker strategies. The company's partnerships and development plans indicate a positive outlook.Read More>---
CGEN Stock 12 Month Forecast
Average Price Target
$4.00
▲(79.37% Upside)
Technical Analysis
Best Analysts Covering CGEN
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
+3.16%
reiterated a buy rating 3 months ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +3.16% per trade.
---